Elanco Animal Health Incorporated is an animal health company that develops and markets products to prevent and treat disease in pets and farm animals. The company operates as a single segment with two primary product categories: pet health and farm animal health. Its pet health portfolio includes parasiticides, dermatology treatments, vaccines, and pain therapeutics, while its farm animal portfolio covers efficiency and performance products, disease prevention and treatment, food safety solutions, and sustainability aids for cattle, poultry, swine, and sheep. Elanco serves customers globally, with the United States as its largest market, followed by Brazil, the United Kingdom, and China. The company was formerly a business unit of Eli Lilly and Company, becoming an independent entity in 2018, and acquired Bayer Animal Health in 2020 to expand its global reach and product balance.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Drug Manufacturers - General Homepage elanco.com
Sector Healthcare IR page elanco.com/us
Tags
animal health, veterinary medicine, parasiticides, vaccines, farm animal health, pet health, cattle, poultry, swine, dogs, cats, Advantage, K-9 Advantix, Advocate, AdTab, Seresto, Credelio, Credelio Cat, Credelio Plus, Credelio Quattro, Zenrelia, TruCan, Trufel, Trutect, Galliprant, Atopica, Drontal, Interceptor Plus, Milbemax, Onsior, Rumensin, Experior, Maxiban, Monteban, AviPro, Baytril, Catosal, Denagard, Hemicell, Pulmotil, Bayer Animal Health, Ivy Animal Health, Reconcile
Press page —

Metrics

Valuation  
Market cap $ 11.494B
Market cap (USD) $ 11.494B
P/E -79.31
PEG —
P/BV 1.73
P/S 2.23
P/OCF 18.72
P/FCF 28.17
Dividend yield —
Turnover / mcap —
Returns  
ROE -3.7%
ROI -2.2%
ROIC 1.8%
Profit margin -4.9%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity 52.0%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 33
Quality score -23.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Revenue 4.715B 4.439B 4.417B 4.411B 4.765B 3.273B 3.071B 3.067B 2.889B
Net profit -232M 338M -1.231B -78M -472M -560.1M 67.9M 86.5M -310.7M
Free cash flow 284M 394M 131M 315M 357M -175.6M 83.7M 352.8M 75.2M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Share price 22.63 12.11 14.9 12.22 28.38 30.67 29.45 31.53 —
Price performance 12m 0.87 -0.19 0.22 -0.57 -0.07 0.04 -0.07 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — 567M 652M 817M 872M 833M 797M 842M 805M 873M
↳ YoY growth +14.9% +25.3% +6.7% -4.4% -4.3% +5.6% -4.4% +8.4%
↳ 5y CAGR +7.0% +5.3% -0.3% +0.0%
Borrowings, current (USD) — 0.00 29M 24.5M 555M 294M 388M 38M 44M 74M
Borrowings, non-current (USD) — 0.00 2.44B 2.33B 5.57B 6.03B 5.45B 5.74B 4.28B 3.94B
Lease liabilities (USD) — — — 85.4M 188M 161M 142M 142M 123M 379M
Cash and deposits (USD) 259M 323M 475M 334M 495M 638M 345M 352M 468M 545M
Intangible assets (USD) — 2.67B 2.45B 2.48B 6.39B 5.59B 4.84B 4.49B 3.68B 3.41B
Right-of-use assets (USD) — — — 85M 187M 161M 141M 140M 122M 116M
Net debt (borrowings + leases - cash) (USD) — -323M 2B 2.11B 5.82B 5.84B 5.63B 5.56B 3.98B 3.85B
Cash flow detail
Operating cash flow (USD) 156M 174M 487M 224M -41M 483M 452M 271M 541M 560M
Purchases of property, plant and equipment (USD) -110M -98.6M -135M -140M -135M -126M -137M -140M -147M -276M
Purchases of intangible assets (USD) — — — 0.00 0.00 -38M -13M -14M -14M —
Change in inventories (cash effect) (USD) -89.1M -39M -20.1M -33.1M -94.7M 27M -269M -160M 44M -57M
Interest paid (cash effect) (USD) — — — -104M -131M -221M -266M -379M -296M -206M
Income taxes paid (cash effect) (USD) -53.6M -35.7M -26.9M -42.5M -97M -151M -93M -95M -140M -225M
Share-based compensation (USD) 20.4M 25M 26M 49.4M 47.7M 66M 59M 46M 55M 68M
Free cash flow (OCF - PPE - intangibles) (USD) 45.6M 75.2M 353M 83.7M -176M 319M 302M 117M 380M 284M
Income detail
Research and development expense (USD) 266M 252M 247M 270M 327M 369M 321M 327M 344M 368M
↳ 5y CAGR +6.8% +5.0% +5.8% +5.0% +2.4%
Total comprehensive income (USD) -283M -110M 64.8M 116M -83.4M -984M -261M -1.11B -167M 398M
Comprehensive income to owners (USD) -283M -110M 64.8M 116M -83.4M -984M -261M -1.11B -167M 398M
Reported Feb 20, 2019 Feb 20, 2019 Feb 20, 2019 Feb 28, 2022 Feb 28, 2022 Feb 28, 2022 Mar 1, 2023 Feb 26, 2024 Feb 25, 2025 Feb 24, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Accelerated Price, Organic Constant Currency Revenue Growth, and Gross Margin Expansion; Raising Full Year Outlook and Innovation Target; Achieved 2.9x Net Leverage Ratio Milestone

•Third Quarter 2026 Financial Results:

◦Revenue of $1.265 billion, an increase of 11% year-over-year; 9% organic constant currency growth

◦Reported Net Income of $18 million, Adjusted Net Income of $136 million

◦Adjusted EBITDA of $243 million; Adjusted EBITDA Margin of 19.5%

◦Reported EPS of $0.04, Adjusted EPS of $0.27

◦Net leverage ratio of 2.9x Adjusted EBITDA

•Full Year 2026 Guidance:

◦Raising innovation revenue target to $1.275 billion

◦Raising revenue guidance to $5.155 billion to $5.18 billion, or approximately 8% organic constant currency growth

◦Raising Adjusted EBITDA guidance to $1.05 billion to $1.065 billion, a year-over-year increase of 17% at midpoint

◦Raising Adjusted EPS guidance to $1.17 to $1.20, a year-over-year increase of 26% at midpoint

◦Improving year-end net leverage ratio target to approximately 2.9x Adjusted EBITDA with accelerated capital allocation flexibility

•2027 Early Outlook:

◦Building on expectations for full year 2026 outperformance, with continued expec

Fall Doesn't Mean the End of Itch and Tick Season  Bull 0 Bear 0 Routine

Posted on October 29, 2026

Share on

A delayed first freeze is stretching parasite and allergy season across the U.S. Here's what that means for your dog. 

A new analysis from Climate Central shows the first fall freeze is arriving later than it did five decades ago.i For dogs, that can mean more weeks of allergic itching and licking, and more weeks of exposure to ticks. The takeaway for pet owners is simple: don't let the calendar decide when you are keeping your pets on parasite or allergy control. 

The first freeze is arriving later 

Climate Central analyzed daily temperature records from 1970 to 2025 for 202 U.S. cities. In 88% of them, the freeze-free stretch of fall has lengthened, by 11 days on average. About one-third of the cities now have a freeze-free fall at least two weeks longer than in the early 1970s.i 

Some of the hardest-hit cities gained more than three weeks including: 

The shift isn't limited to one part of the country. Cities in every U.S. climate region saw their fall seasons lengthen, with the Northwest seeing the largest regional gain at 14 days on average. 

That extra time matters because a hard freeze is what shuts down ragweed, one of the biggest fall allergy triggers. A single ragweed plant can release up to a billion pollen grains, and the length of ragweed season is closely tied to the number of days before the first frost.  

A longer season for itchy dogs 

People aren't the only ones who feel it when pollen sticks around. Dogs with environmental allergies often react to the same pollens and molds, but their symptoms tend to show up in their skin rather than as sneezing. Itch is wide spread: Elanco's America's Itchy Dogs Report found that nearly 9 in 10 U.S. dogs are “itchy dogs”, having experienced itchiness at some point during the year and 94% of veterinarians believe that dog owners do not realize how much discomfort their dog is in when they scratch themselves.ii 

Common signs of canine allergic itch include: 

  • Persistent scratching, licking, chewing or biting at the coat and skin 
  • Red, irritated skin, hair loss or hot spots 
  • Sore, inflamed paws, and/or constant paw licking 

Chronic itch takes a toll on the whole household. It can disrupt sleep for pets and their families, and constant scratching can break the skin and lead to further problems. With more freeze-free days, symptoms that once eased by October may now linger well into November. 

Ticks don't clock out when summer ends 

Mild fall weather keeps ticks going, too. Ticks can be active at temperatures as low as 35 degreesiii, so a chilly morning or a brief cold snap doesn't mean the risk has passed. In fact, CDC data typically shows a second peak in emergency department visits for tick bites in October and November. 

Dogs feel that risk as well. One study of tick photos submitted from companion animals found that 28.5% came in autumn and another 35.2% in winter.iv  Ticks can carry diseases that affect both dogs and humans, so it‘s important to stay vigilant during cooler temperatures. For pet owners, these changes drive the need to keep their dogs on consistent, year-round parasite control rather than a seasonal start-and-stop approach. 

How to help your dog this fall 

  • Stay on parasite control year-round. Don't pause coverage just because temperatures drop. Many pet owners may choose a 6-month prescription, so it’s important to renew prescriptions before the start of the new year if they are expiring.  
  • Do regular tick checks. After walks, hikes or time in tall grass and leaf piles, check your dog's ears, neck, armpits and between the toes. 
  • Wipe down after outdoor time. A quick wipe of paws and coat can help remove pollen before it settles in. 
  • Keep notes on itching. Track when scratching, licking or chewing starts and how often it happens, so you can share the pattern with your veterinarian. 
  • Talk to your veterinarian. If itching persists or skin looks red, raw or irritated, your veterinarian can help identify the cause and recommend options for relief and prevention. 

For the animal health industry, this is an important reminder of why education, protection and innovation matter year-round. At Elanco, we believe that making life better for animals includes anticipating needs and creating solutions for pet owners and veterinarians.

i Climate Central. (2026, September 23). Warmer fall, later freeze, longer allergy season. https://www.climatecentral.org/climate-matters/fall-allergy-season

ii Elanco Animal Health. Data on File. REF-28442

iii Clark DD. Lower temperature limits for activity of several Ixodid ticks (Acari: Ixodidae): effects of body size and rate of temperature change. J Med Entomol. 1995;32(4):449-52.

iv Kopsco HL, Duhaime RJ, Mather TN. An analysis of companion animal tick encounters as revealed by photograph-based crowdsourced data. Vet Med Sci. 2021 Nov;7(6):2198-2208. doi: 10.1002/vms3.586. Epub 2021 Aug 20. PMID: 34414695; PMCID: PMC8604111.

About Elanco

At Elanco, we are united by a genuine love and care for animals. Our purpose - making life better for animals, makes life better - fuels us to break boundaries and inspires us to push further, transforming animal care for healthier animals and a healthier, more sustainable world.

Our Company

About Us

Contact Us

Suppliers

Terms and Conditions of Sale

Brand Protection

What's Happening

Newsroom

Press Releases

Featured Articles

Join Elanco

Search Jobs

Careers

Benefits

Students and Graduates

Investor Relations

Investor Overview

Stock Information

Financial Filings

Investor Resources

Investor Events

Governance

Connect with

Connect with Elanco

Elanco Logo

United States

Elanco's Healthy Purpose, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. © 2026 Elanco or its affiliates.

Our Company

What's Happening

Join Elanco

Investor Relations

About Elanco

Exterior photo of Elanco global headquarter building

At Elanco, we are united by a genuine love and care for animals. Our purpose - making life better for animals, makes life better - fuels us to break boundaries and inspires us to push further, transforming animal care for healthier animals and a healthier, more sustainable world.

Connect with

Connect with Elanco

United States

Elanco's Healthy Purpose, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. © 2026 Elanco or its affiliates.

Elanco Logo

Posted on October 22, 2026

Share on

Preston brings more than two decades of global HR leadership and workforce innovation experience; Dave Kinard to retire at year-end

INDIANAPOLIS (October 22, 2026) – Elanco Animal Health Incorporated (NYSE: ELAN) today announced the appointment of Jamie Preston as Executive Vice President and Chief People Officer, effective November 3rd. Preston’s appointment follows an extensive and competitive search as part of the company's commitment to attract, develop and retain an engaged global workforce while embedding inclusion, well-being and purpose into daily operations. Preston succeeds Dave Kinard, who intends to retire at the end of the year. Kinard will work closely with Preston in the coming months to ensure a seamless leadership transition. 

Preston joins Elanco from Eli Lilly and Company, bringing 23 years of enterprise experience, including nearly two decades of human resources leadership. Most recently serving as Vice President of HR, Global Compensation and Workforce Innovation, where Preston led the compensation and recognition team for Lilly’s global 50,000+ employee organization and spearheaded enterprise-wide AI and workforce modernization strategies. 

“Jamie is a visionary, dynamic leader with the speed and agility that defines Elanco.  She has deep global experience across every facet of human resources, from organizational design and talent development to workforce innovation and digital transformation," said Jeff Simmons, President and CEO of Elanco. "As Elanco continues to drive growth and deliver on our purpose of enriching the lives of animals and people, Jamie’s proven track record of building high-performing, inclusive cultures and shaping forward-looking workforce strategies makes her an ideal fit for our executive team. Her shared heritage with our roots at Lilly brings a deep understanding of values-based, science-driven organizations.” 

During her tenure at Lilly - which started in the sales organization - Preston held executive HR leadership roles spanning global markets, including serving as Associate Vice President of HR across five countries in the Asia-Pacific region (Australia, New Zealand, Taiwan, Korea, and Hong Kong), where she supported the region's growth into a billion-dollar business hub. She also previously served as HR Director for Lilly Japan, supporting the research and development organization, led global people strategy for the Oncology Business Unit and supported key corporate and manufacturing functions.  

“Elanco’s purpose - food and companionship enriching lives - deeply resonates with me,” said Jamie Preston. I am excited to partner with our global teams to champion our people, advance workforce innovation and cultivate a culture where our talent thrives as we deliver for veterinarians, pet owners, farmers and the animals in their care.” 

Beyond her corporate leadership, Preston is an active contributor to community and industry organizations. She serves on the board of directors for Teach for America, Indianapolis and previously served on the board of Cancer Support Community Central Indiana.  

Preston completed the Chief Human Resources Officer (CHRO) Program at the Wharton School at the University of Pennsylvania and holds both a master’s and a bachelor’s degree in health service administration from the University of Evansville. 

Honoring Dave Kinard's Leadership 

Kinard’s upcoming retirement marks the culmination of a distinguished career dedicated to organizational excellence and talent development. Since Elanco’s transition from Lilly’s animal health division to a publicly traded, independent company, Kinard has played a foundational role in shaping Elanco’s global HR infrastructure, culture and employee experience. 

Kinard oversaw all aspects of the company's headquarters move from Greenfield to Indianapolis, including the establishment of the "One Health Innovation District," a purpose-built life sciences innovation hub anchored by Elanco and Purdue University.  

“Today our employee engagement is the highest since our IPO, backed by a culture and brand in a position of strength because of Dave’s dedicated leadership and enduring contributions,” added Simmons. "Dave has been a trusted partner, and we appreciate his commitment to supporting Jamie through the end of the year to ensure continuity for our teams around the world, and we wish him all the best in his well-deserved retirement." 

ABOUT ELANCO 

Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With more than 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our purpose – all to Go Beyond for Animals, Customers, Society and Our People. Learn more at www.elanco.com.


Media Contact

Keri McGrath

+1.317.370.8394

[email protected]

Contact

Investor Contact

Tiffany Kanaga

+1.765.740.0314

[email protected]

Contact

About Elanco

At Elanco, we are united by a genuine love and care for animals. Our purpose - making life better for animals, makes life better - fuels us to break boundaries and inspires us to push further, transforming animal care for healthier animals and a healthier, more sustainable world.

Our Company

About Us

Contact Us

Suppliers

Terms and Conditions of Sale

Brand Protection

What's Happening

Newsroom

Press Releases

Featured Articles

Join Elanco

Search Jobs

Careers

Benefits

Students and Graduates

Investor Relations

Investor Overview

Stock Information

Financial Filings

Investor Resources

Investor Events

Governance

Connect with

Connect with Elanco

Elanco Logo

United States

Elanco's Healthy Purpose, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. © 2026 Elanco or its affiliates.

Our Company

What's Happening

Join Elanco

Investor Relations

About Elanco

Exterior photo of Elanco global headquarter building

At Elanco, we are united by a genuine love and care for animals. Our purpose - making life better for animals, makes life better - fuels us to break boundaries and inspires us to push further, transforming animal care for healthier animals and a healthier, more sustainable world.

Connect with

Connect with Elanco

United States

Elanco's Healthy Purpose, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. © 2026 Elanco or its affiliates.

Elanco Logo

Prompts

Elanco Animal Health Incorporated (ticker ELAN), listed in United States.

Company History

Date Change Detail
May 9, 2019 Acquired Acquired Aratana Therapeutics, Inc. (CIK 1509190). Its filings from before the deal are on its own company page, not shown here.

ETFs Holding Elanco Animal Health Incorporated

ETF Weight in ETF Shares Market value As of
BSMC 2.65% 179,277 $ 4.412M Jun 30, 2026
JHAC 2.21% 3,179 $ 78.235K Jun 30, 2026
TMED 1.91% 17,864 $ 439.633K Jun 30, 2026
BCSM 1.71% 23,039 $ 566.99K Jun 30, 2026
LSEQ 1.00% 6,275 $ 168.045K Nov 13, 2026
TSME 0.95% 403,629 $ 9.933M Jun 30, 2026
DFSV 0.87% 9,040,630 $ 239.577M Nov 12, 2026
DFAT 0.49% 5,779,327 $ 153.152M Nov 12, 2026
CGMM 0.48% 652,436 $ 17.231M Nov 16, 2026
BTAL short -0.43% -49,082 $ -1.208M Jun 30, 2026
ITAN 0.37% 17,543 $ 453.487K Nov 17, 2026
FFSM 0.34% 195,287 $ 5.15M Jul 31, 2026
LCDS 0.34% 2,109 $ 54.518K Nov 17, 2026
JOYT 0.33% 15,185 $ 392.532K Nov 17, 2026
NANC 0.31% 31,671 $ 836.431K Nov 17, 2026
MCDS 0.27% 806 $ 20.835K Nov 17, 2026
DFAS 0.27% 3,368,098 $ 89.255M Nov 12, 2026
CDX short -0.25% -24,233.4353 $ -626.434K Nov 17, 2026
FLCC 0.24% 13,523 $ 323.47K Aug 31, 2026
FMDE 0.23% 698,707 $ 17.195M Jun 30, 2026
MKTN 0.23% 9,785 $ 240.809K Jun 30, 2026
FEMV 0.20% 426 $ 10.484K Jun 30, 2026
FLCV 0.17% 10,080 $ 241.114K Aug 31, 2026
JMEE 0.16% 180,966 $ 4.678M Nov 17, 2026
AVMC 0.13% 27,980 $ 738.952K Nov 16, 2026
TMSL 0.13% 140,601 $ 3.46M Jun 30, 2026
AVIE 0.10% 644 $ 17.008K Nov 16, 2026
SMDX 0.09% 4,287 $ 113.22K Nov 17, 2026
DXUV 0.09% 209,017 $ 5.539M Nov 12, 2026
VFMO 0.09% 70,678 $ 1.691M Aug 31, 2026
FEAC 0.08% 842 $ 20.722K Jun 30, 2026
DFUV 0.07% 410,820 $ 10.887M Nov 12, 2026
MSSM 0.07% 20,704 $ 495.24K Aug 31, 2026
FBCG 0.06% 165,538 $ 4.365M Jul 31, 2026
DFAC 0.06% 1,987,922 $ 52.68M Nov 12, 2026
VFVA 0.05% 18,420 $ 440.606K Aug 31, 2026
DCOR 0.03% 531,543 $ 14.086M Nov 12, 2026
IALT short -0.03% -92,344 $ -2.439M Nov 16, 2026
DFAU 0.02% 119,633 $ 3.17M Nov 12, 2026
AVUS 0.02% 90,753 $ 2.397M Nov 16, 2026
AVSU 0.02% 3,796 $ 100.252K Nov 16, 2026
AVLC 0.02% 14,464 $ 381.994K Nov 16, 2026
INRO 0.02% 5,317 $ 140.422K Nov 16, 2026
DFUS 0.02% 153,106 $ 4.057M Nov 12, 2026
EBI 0.02% 4,638 $ 110.941K Aug 31, 2026
MSLC 0.01% 18,983 $ 454.073K Aug 31, 2026
NTRL short 0.00% -4,538 $ 0.00 Nov 16, 2026